TY - JOUR T1 - Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET): Experience at Three Institutions JF - Anticancer Research JO - Anticancer Res SP - 2175 LP - 2177 VL - 33 IS - 5 AU - MUHAMMAD WASIF SAIF AU - ROGER OVE AU - JOHN NG AU - SUZANNE RUSSO Y1 - 2013/05/01 UR - http://ar.iiarjournals.org/content/33/5/2175.abstract N2 - Aim: Advanced pancreatic neuroendocrine tumor (PNET) presents a therapeutic challenge as many are unresectable and relatively resistant to systemic therapy with a high malignant potential. We share our experience using concurrent capecitabine or infusional 5-fluorouracil with radiation for patients with resected and locally advanced PNET. Patients and Methods: Six patients (two females, four males) with PNET were treated with capecitabine or infusional 5-FU and concurrent radiation. Results: The median age was 52 years (range: 38 to 63 years), with ECOG Performance Status (PS) 0-1, grade 0-1 weight loss, and grade 0-1 pain. One patient underwent resection with negative margins, two with positive margins, and three had unresectable locally advanced disease. All six patients demonstrated partial radiographic response and sustained local control. The treatment was tolerable with only grade 2 hand-foot syndrome and grade 1 mucositis observed. Conclusion: Prospective studies to further investigate the role of chemoradiation in this setting are warranted. ER -